REGENXBIO (NASDAQ:RGNX) Insider Sells 36,725 Shares

REGENXBIO Inc. (NASDAQ:RGNX) insider Steve Pakola sold 36,725 shares of the company’s stock in a transaction on Wednesday, July 1st. The stock was sold at an average price of $12.86, for a total transaction of $472,283.50. Following the completion of the transaction, the insider directly owned 213,009 shares of the company’s stock, valued at approximately $2,739,295.74. The trade was a 14.71% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website.

Steve Pakola also recently made the following trade(s):

• On Monday, June 29th, Steve Pakola sold 19,608 shares of REGENXBIO stock. The stock was sold at an average price of $11.04, for a total transaction of $216,472.32.
• On Monday, May 11th, Steve Pakola sold 15,309 shares of REGENXBIO stock. The shares were sold at an average price of $11.02, for a total value of $168,705.18.

REGENXBIO Price Performance

NASDAQ RGNX traded up $1.11 on Wednesday, reaching $13.09. The stock had a trading volume of 4,456,460 shares, compared to its average volume of 2,291,967. REGENXBIO Inc. has a 1-year low of $5.45 and a 1-year high of $16.19. The firm has a fifty day moving average of $8.12 and a two-hundred day moving average of $9.91. The company has a market cap of $676.75 million, a P/E ratio of -2.34 and a beta of 0.90.

REGENXBIO (NASDAQ:RGNX) last posted its quarterly earnings results on Thursday, May 14th. The biotechnology company reported ($1.72) EPS for the quarter, missing analysts’ consensus estimates of ($1.36) by ($0.36). The business had revenue of $6.39 million for the quarter, compared to analyst estimates of $25.84 million. REGENXBIO had a negative return on equity of 232.50% and a negative net margin of 330.23%. Research analysts predict that REGENXBIO Inc. will post -3.69 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research firms recently issued reports on RGNX. HC Wainwright restated a “buy” rating and set a $26.00 price objective on shares of REGENXBIO in a report on Wednesday. Leerink Partners raised their target price on REGENXBIO from $17.00 to $18.00 and gave the stock an “outperform” rating in a research note on Monday, June 22nd. Barclays lowered their price target on shares of REGENXBIO from $37.00 to $12.00 and set an “overweight” rating for the company in a research note on Friday, May 15th. Weiss Ratings restated a “sell (e+)” rating on shares of REGENXBIO in a report on Monday, June 8th. Finally, Robert W. Baird increased their target price on REGENXBIO from $27.00 to $32.00 and gave the stock an “outperform” rating in a research report on Monday, June 22nd. Ten analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $23.82.

Institutional Investors Weigh In On REGENXBIO

Several hedge funds and other institutional investors have recently added to or reduced their stakes in RGNX. Aquatic Capital Management LLC purchased a new stake in shares of REGENXBIO in the third quarter worth $37,000. Captrust Financial Advisors purchased a new stake in REGENXBIO during the second quarter valued at $85,000. Entropy Technologies LP purchased a new stake in REGENXBIO in the 1st quarter worth about $87,000. Prudential Financial Inc. purchased a new stake in REGENXBIO in the second quarter worth $87,000. Finally, CANADA LIFE ASSURANCE Co raised its stake in shares of REGENXBIO by 271.8% during the second quarter. CANADA LIFE ASSURANCE Co now owns 10,839 shares of the biotechnology company’s stock valued at $89,000 after acquiring an additional 7,924 shares in the last quarter. 88.08% of the stock is owned by hedge funds and other institutional investors.

About REGENXBIO

REGENXBIO Inc is a clinical?stage biotechnology company specializing in the development of gene therapies using its proprietary NAV® AAV (adeno?associated virus) platform. The company engineers next?generation AAV vectors designed to deliver functional genes to targeted cells, aiming to address a range of rare genetic diseases and ocular, metabolic and neurologic disorders. REGENXBIO’s pipeline features several product candidates in various stages of preclinical and clinical development, including RGX-314 for wet age?related macular degeneration, RGX-121 for mucopolysaccharidosis II (Hunter syndrome) and RGX-121 for other rare lysosomal storage diseases.

In addition to its internally funded programs, REGENXBIO has established partnerships with major biopharmaceutical companies to advance its NAV technology.